ArticleMolecules (Basel, Switzerland)2015
Antiviral, Antifungal and Antibacterial Activities of a BODIPY-Based Photosensitizer.
Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 101 citations in OpenAlex.
- Photoinduced Inactivation of Pathogenic Microorganisms via Cotton Textile Functionalized with a Novel Iodinated BODIPY Derivative.Molecules (Basel, Switzerland) · 2026Article
- Anionic Boron-Cluster BODIPY Conjugates As Promising Photosensitizers for Targeted Antimicrobial Photodynamic Therapy.ACS omega · 2025Article
- Membrane-Targeting Antivirals.International journal of molecular sciences · 2025Review
- Current Strategies for Combating Biofilm-Forming Pathogens in Clinical Healthcare-Associated Infections.Indian journal of microbiology · 2024Review
- Antimicrobial Photodynamic Therapy: Self-Disinfecting Surfaces for Controlling Microbial Infections.Microorganisms · 2024Review
- Designing Antitrypanosomal and Antileishmanial BODIPY Derivatives: A Computational and In Vitro Assessment.Molecules (Basel, Switzerland) · 2024Article
- What can we learn from treatments of oral lichen planus?Frontiers in cellular and infection microbiology · 2024Review
- Lipid-Centric Approaches in Combating Infectious Diseases: Antibacterials, Antifungals and Antivirals with Lipid-Associated Mechanisms of Action.Antibiotics (Basel, Switzerland) · 2023Review
- Alkyl Derivatives of Perylene Photosensitizing Antivirals: Towards Understanding the Influence of Lipophilicity.International journal of molecular sciences · 2023Article
- Membrane-Targeting Perylenylethynylphenols Inactivate Medically Important Coronaviruses via the Singlet Oxygen Photogeneration Mechanism.Molecules (Basel, Switzerland) · 2023Article
- 8(Molecules (Basel, Switzerland) · 2023Article
- Near-Infrared Dyes: Towards Broad-Spectrum Antivirals.International journal of molecular sciences · 2022Review
- Porphyrin nanoemulsion for antimicrobial photodynamic therapy: effective delivery to inactivate biofilm-related infections.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Selenophene-Modified Boron Dipyrromethene-Based Photosensitizers Exhibit Photodynamic Inhibition on a Broad Range of Bacteria.ACS omega · 2022Article
- A Comparison of the Photophysical, Electrochemical and Cytotoxic Properties ofSensors (Basel, Switzerland) · 2022Article
- Searching for antimicrobial photosensitizers among a panel of BODIPYs.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022Article
- Recent Strategies to Combat Biofilms Using Antimicrobial Agents and Therapeutic Approaches.Pathogens (Basel, Switzerland) · 2022Review
- Self-luminescent photodynamic therapy and pathogen detection for infectious diseases.Drug delivery and translational research · 2021Review
- Photosensitizing Antivirals.Molecules (Basel, Switzerland) · 2021Review
- Photoinactivation of mycobacteria to combat infection diseases: current state and perspectives.Applied microbiology and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial photodynamic inactivation (aPDI) employing the BODIPY-based photosensitizer 2,6-diiodo-1,3,5,7-tetramethyl-8-(N-methyl-4-pyridyl)-4,4'-difluoro-boradiazaindacene (DIMPy-BODIPY) was explored in an in vitro assay against six species of bacteria (eight total strains), three species of yeast, and three viruses as a complementary approach to their current drug-based or non-existent treatments. Our best results achieved a noteworthy 5-6 log unit reduction in CFU at 0.1 μM for Staphylococcus aureus (ATCC-2913), methicillin-resistant S. aureus (ATCC-44), and vancomycin-resistant Enterococcus faecium (ATCC-2320), a 4-5 log unit reduction for Acinetobacter baumannii ATCC-19606 (0.25 μM), multidrug resistant A. baumannii ATCC-1605 (0.1 μM), Pseudomonas aeruginosa ATCC-97 (0.5 μM), and Klebsiella pneumoniae ATCC-2146 (1 μM), and a 3 log unit reduction for Mycobacterium smegmatis mc2155 (ATCC-700084). A 5 log unit reduction in CFU was observed for Candida albicans ATCC-90028 (1 μM) and Cryptococcus neoformans ATCC-64538 (0.5 μM), and a 3 log unit reduction was noted for Candida glabrata ATCC-15545 (1 μM). Infectivity was reduced by 6 log units in dengue 1 (0.1 μM), by 5 log units (0.5 μM) in vesicular stomatitis virus, and by 2 log units (5 μM) in human adenovirus-5. Overall, the results demonstrate that DIMPy-BODIPY exhibits antiviral, antibacterial and antifungal photodynamic inactivation at nanomolar concentrations and short illumination times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.